Screener
Veracyte VCYT Gross Profit
Gross Profit at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of biopharmaceutical and other revenue | 8 | 2,698 |
| Intangible asset amortization - cost of revenue | 2,707 | 2,585 |
| Total cost of revenue | 37,912 | 34,965 |
| Gross profit | 101,159 | 79,508 |
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's gross profit?
- Veracyte (VCYT) reported gross profit of $101.16M in Q1 2026.
- How has Veracyte's gross profit changed year-over-year?
- Veracyte's gross profit increased by 27.2% year-over-year, from $79.51M to $101.16M.
- What is the long-term trend for Veracyte's gross profit?
- Over 3 years (2022 to 2025), Veracyte's gross profit has grown at a 27.3% compound annual growth rate (CAGR), from $175.68M to $362.53M.
- What does gross profit mean?
- Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.
Ask your AI about Veracyte's gross profit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude